Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 9/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | NOS1 | P29475 | 9/20 | 0.72 |
| ▸ | NOS3 | P29474 | 5/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | DDAH1 | O94760 | 6/20 | 0.68 |
| ▸ | THPO | P40225 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL43261 | 1.00 | NOS2 (1.00) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL30679324 | 1.00 | NOS2 (1.00) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL30577923 | 1.00 | NOS2 (1.00) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL30631154 | 1.00 | NOS2 (1.00) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL288835 | 1.00 | NOS2 (1.00) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL31547986 | 0.98 | NOS2 (0.96) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL30074239 | 0.98 | NOS2 (0.96) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL29361849 | 0.98 | NOS2 (0.96) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL15152867 | 0.96 | NOS2 (0.92) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL1532506 | 0.96 | NOS2 (0.92) | NOS2CYP2C19CYP1A2TSHRGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3365354-B1 | PEPTIDES AND PEPTIDOMIMETICS IN COMBINATION WITH T CELL ACTIVATING AND/OR CHECKPOINT INHIBITING AGENTS FOR CANCER TREATMENT | CANBAS CO LTD (JP) | 2026-02-11 | — | — | EP | claimed |
| EP-4536684-A1 | INTERLEUKIN-13 BINDING CYCLIC OLIGOPEPTIDES AND METHODS OF USE THEREOF | B.A.I. Laboratories, LLC (US) | 2025-04-16 | — | — | EP | claimed |
| CN-119630685-A | Cyclic oligopeptides that bind interleukin-13 and methods of use thereof | B.A.I.实验室有限责任公司 | 2025-03-14 | — | — | CN | claimed |
| US-12239714-B2 | Phosphatidylserine-binding conjugates | CANBAS CO., LTD. (JP) | 2025-03-04 | — | — | US | claimed |
| US-20250011777-A1 | DELIVERY OF ANITSENSE OLIGOMERS BY MIRROR IMAGE PEPTIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2025-01-09 | — | — | US | claimed |
| EP-4456923-A1 | CONJUGATES BINDING PHOSPHATIDYLSERINE AND TOLL-LIKE RECEPTORS | CanBas Co., Ltd. (JP) | 2024-11-06 | — | — | EP | claimed |
| CN-118574643-A | Conjugates that bind phosphatidylserine and Toll-like receptors | 三井有限公司 | 2024-08-30 | — | — | CN | claimed |
| CN-118440156-A | Bionic cyclic peptide and application thereof | 郑州大学第一附属医院 | 2024-08-06 | — | — | CN | claimed |
| EP-4387676-A2 | DELIVERY OF ANITSENSE OLIGOMERS BY MIRROR IMAGE PEPTIDES | Sarepta Therapeutics, Inc. (US) | 2024-06-26 | — | — | EP | claimed |
| WO-2023245016-A1 | INTERLEUKIN-13 BINDING CYCLIC OLIGOPEPTIDES AND METHODS OF USE THEREOF | B.A.I. LABORATORIES, LLC (US) | 2023-12-21 | — | — | WO | claimed |
| US-20230399362-A1 | INTERLEUKIN-13 BINDING CYCLIC OLIGOPEPTIDES AND METHODS OF USE THEREOF | B.A.I. LABORATORIES, LLC | 2023-12-14 | — | — | US | claimed |
| US-20230310540-A1 | PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | 2023-10-05 | — | — | US | claimed |
| US-20230270869-A1 | PHOSPHATIDYLSERINE-BINDING CONJUGATES | CANBAS CO., LTD. (JP) | 2023-08-31 | — | — | US | claimed |
| US-20230220010-A1 | BROAD-SPECTRUM ANTIVIRAL PEPTIDES | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | 2023-07-13 | — | — | US | claimed |
| WO-2023126885-A1 | CONJUGATES BINDING PHOSPHATIDYLSERINE AND TOLL-LIKE RECEPTORS | CANBAS CO., LTD. (JP) | 2023-07-06 | — | — | WO | claimed |
| WO-2023034515-A2 | DELIVERY OF ANITSENSE OLIGOMERS BY MIRROR IMAGE PEPTIDES | SAREPTA THERAPEUTICS, INC. (US) | 2023-03-09 | — | — | WO | claimed |
| EP-4110467-A1 | BROAD-SPECTRUM ANTIVIRAL PEPTIDES | The Administrators of the Tulane Educational Fund (US) | 2023-01-04 | — | — | EP | claimed |
| EP-4087595-A1 | PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF | The Administrators of the Tulane Educational Fund (US) | 2022-11-16 | — | — | EP | claimed |
| US-11266743-B2 | Peptide compositions and methods of use thereof | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2022-03-08 | — | — | US | claimed |
| US-20260125426-A1 | CYCLIC CELL-PENETRATING PEPTIDES AND USES THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260115301-A1 | INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4717776-A2 | POLYPEPTIDE CONJUGATES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | Ohio State Innovation Foundation (US) | 2026-04-01 | — | — | EP | disclosed |
| CN-121673388-A | Mu-type conotoxin peptide mutant, pharmaceutical composition and application thereof | 深圳肽盛生物科技有限公司 | 2026-03-17 | — | — | CN | disclosed |
| US-20260073030-A1 | METHODS, SYSTEMS, APPARATUSES, AND DEVICES FOR FACILITATING SELF-OPTIMIZABLE BIOMETRIC IDENTITY VERIFICATION OF USERS | LIU JIAN (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260069656-A1 | Nutritive Polypeptides and Formulations Thereof, and Methods of Production and Use Thereof | AXCELLA HEALTH INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260070948-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH CARGO | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260070947-A1 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4706689-A2 | COMPOSITIONS FOR DELIVERY OF ANTISENSE COMPOUNDS | Entrada Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-3999094-B1 | A UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-TARGETING PEPTIDE | RIGSHOSPITALET (DK) | 2026-02-25 | — | — | EP | disclosed |
| EP-4225772-B1 | CYCLIC APELIN RECEPTOR AGONISTS | NXERA PHARMA UK LTD (GB) | 2026-02-25 | — | — | EP | disclosed |
| EP-3365354-B1 | PEPTIDES AND PEPTIDOMIMETICS IN COMBINATION WITH T CELL ACTIVATING AND/OR CHECKPOINT INHIBITING AGENTS FOR CANCER TREATMENT | CANBAS CO LTD (JP) | 2026-02-11 | — | — | EP | disclosed |
| EP-4684030-A2 | METHOD OF DEPROTECTING AT LEAST ONE D-AMINO ACID AND/OR D-AMINO ACID DERIVATIVE PROTECTED FUNCTIONAL GROUP | Martin-Luther-Universität Halle-Wittenberg (DE) | 2026-01-28 | — | — | EP | disclosed |
| US-12528840-B2 | Transcription active complex targeting cancer drug from viral protein sequence | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-20 | — | — | US | disclosed |
| US-20260008812-A1 | CELL-PENETRATING PEPTIDE COMPOUNDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-01-08 | — | — | US | disclosed |
| US-20260008813-A1 | CELL-PENETRATING PEPTIDE COMPOUNDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-01-08 | — | — | US | disclosed |
| US-20260001916-A1 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-01-01 | — | — | US | disclosed |
| US-12508295-B2 | Piscine-derived PYY peptides for use in treating a metabolic disorder | UNIVERSITY OF ULSTER (GB) | 2025-12-30 | — | — | US | disclosed |
| US-12496350-B2 | Cyclic peptidyl inhibitors of CAL-PDZ binding domain | OHIO STATE INNOVATION FOUNDATION (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4652180-A2 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Janssen Pharmaceutica NV (BE) | 2025-11-26 | — | — | EP | disclosed |
| EP-4652179-A1 | LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Janssen Pharmaceutica NV (BE) | 2025-11-26 | — | — | EP | disclosed |
| US-20250352593-A1 | USE OF A MICROALGAE EXTRACT, ALONE OR IN COMBINATION, FOR IMPROVING COGNITIVE ABILITIES | MICROPHYT (FR) | 2025-11-20 | — | — | US | disclosed |
| US-12441777-B2 | GLP-1 receptor antagonists | NXERA PHARMA UK LIMITED (GB) | 2025-10-14 | — | — | US | disclosed |
| US-20250282834-A1 | PEPTIDE INHIBITORS FOR CHROMODOMAIN HELICASE DNA BINDING PROTEIN 4 (CHD4) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-09-11 | — | — | US | disclosed |
| US-20250276996-A1 | CATIONICALLY-ENFRAMED HIGH DENSITY AROMATIC PEPTIDES | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK | 2025-09-04 | — | — | US | disclosed |
| US-20250270258-A1 | BICYCLIC PEPTIDYL INHIBITORS | OHIO STATE INNOVATION FOUNDATION | 2025-08-28 | — | — | US | disclosed |
| US-12329799-B2 | Peptidyl inhibitors of calcineurin-NFAT interaction | OHIO STATE INNOVATION FOUNDATION (US) | 2025-06-17 | — | — | US | disclosed |
| EP-4562025-A2 | CYCLIC CELL-PENETRATING PEPTIDES AND USES THEREOF | Ohio State Innovation Foundation (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2025108181-A1 | POLYPEPTIDE-CONJUGATED DRUG, METHOD FOR PREPARING SAME, AND USE THEREOF | 湖南中晟全肽生物科技股份有限公司 | 2025-05-30 | — | — | WO | disclosed |
| US-20250171762-A1 | THERAPEUTICAL PEPTIDOMIMETIC | UNIVERSITA' DEGLI STUDI DI ROMA "LA SAPIENZA" (IT) | 2025-05-29 | — | — | US | disclosed |
| CN-120019818-A | Polypeptide coupling medicine and preparation method and application thereof | 湖南中晟全肽生物科技股份有限公司 | 2025-05-20 | — | — | CN | disclosed |
| CN-119954923-A | New mu-type conotoxin peptide, pharmaceutical composition and application thereof | 苏州华肽鹏诚生物制造有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119954923-A | New mu-type conotoxin peptide, pharmaceutical composition and application thereof | 苏州华肽鹏诚生物制造有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20250145666-A1 | INTERLEUKIN-13 BINDING CYCLIC OLIGOPEPTIDES AND METHODS OF USE THEREOF | B.A.I. LABORATORIES, LLC | 2025-05-08 | — | — | US | disclosed |
| CN-119912548-A | Mu-type conotoxin peptide mutant, pharmaceutical composition and application thereof | 苏州华肽鹏诚生物制造有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-119912548-A | Mu-type conotoxin peptide mutant, pharmaceutical composition and application thereof | 苏州华肽鹏诚生物制造有限公司 | 2025-05-02 | — | — | CN | disclosed |
| US-12281181-B2 | Bicyclic peptidyl inhibitors | OHIO STATE INNOVATION FOUNDATION (US) | 2025-04-22 | — | — | US | disclosed |
| CN-119838016-A | A pharmaceutical composition with broad-spectrum anti-infectious and broad-spectrum anticancer effects | 单立华 | 2025-04-18 | — | — | CN | disclosed |
| EP-4536684-A1 | INTERLEUKIN-13 BINDING CYCLIC OLIGOPEPTIDES AND METHODS OF USE THEREOF | B.A.I. Laboratories, LLC (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20250115885-A1 | COMPOSITIONS AND METHODS FOR TREATING MITOCHONDRIAL NEUROGASTROINTESTINAL ENCEPHALOPATHY | ENTRADA THERAPEUTICS, INC. | 2025-04-10 | — | — | US | disclosed |
| US-20250090675-A1 | POLYPEPTIDE CONJUGATES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | OHIO STATE INNOVATION FOUNDATION | 2025-03-20 | — | — | US | disclosed |
| CN-119630685-A | Cyclic oligopeptides that bind interleukin-13 and methods of use thereof | B.A.I.实验室有限责任公司 | 2025-03-14 | — | — | CN | disclosed |
| US-12239714-B2 | Phosphatidylserine-binding conjugates | CANBAS CO., LTD. (JP) | 2025-03-04 | — | — | US | disclosed |
| US-20250011777-A1 | DELIVERY OF ANITSENSE OLIGOMERS BY MIRROR IMAGE PEPTIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2025-01-09 | — | — | US | disclosed |
| US-12180307-B2 | Interleukin-13 binding cyclic oligopeptides and methods of use thereof | B.A.I. LABORATORIES, LLC (US) | 2024-12-31 | — | — | US | disclosed |
| US-12171838-B2 | Polypeptide conjugates for intracellular delivery of nucleic acids | OHIO STATE INNOVATION FOUNDATION (US) | 2024-12-24 | — | — | US | disclosed |
| CN-119055784-A | Carbon dot-amino acid composite reagent and preparation method and application thereof | 澳门大学 | 2024-12-03 | — | — | CN | disclosed |
| WO-2024227957-A2 | METHOD OF DEPROTECTING AT LEAST ONE D-AMINO ACID AND/OR D-AMINO ACID DERIVATIVE PROTECTED FUNCTIONAL GROUP | Martin-Luther-Universität Halle-Wittenberg (DE) | 2024-11-07 | — | — | WO | disclosed |
| US-20240368227-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH ONE OR MORE HYDROPHOBIC RESIDUES | OHIO STATE INNOVATION FOUNDATION | 2024-11-07 | — | — | US | disclosed |
| EP-4456909-A1 | THERAPEUTICAL PEPTIDOMIMETIC | Università degli Studi di Roma "La Sapienza" (IT) | 2024-11-06 | — | — | EP | disclosed |
| EP-4456923-A1 | CONJUGATES BINDING PHOSPHATIDYLSERINE AND TOLL-LIKE RECEPTORS | CanBas Co., Ltd. (JP) | 2024-11-06 | — | — | EP | disclosed |
| US-20240360174-A1 | CELL-PENETRATING PEPTIDE SEQUENCES | OHIO STATE INNOVATION FOUNDATION | 2024-10-31 | — | — | US | disclosed |
| CN-114555623-B | Urokinase plasminogen activator receptor targeting peptides | 丹麦国家医院 | 2024-10-25 | — | — | CN | disclosed |
| US-12115224-B2 | Polypeptide conjugates for intracellular delivery of stapled peptides | OHIO STATE INNOVATION FOUNDATION (US) | 2024-10-15 | — | — | US | disclosed |
| US-20240307428-A1 | SYNERGISTIC COMPOSITION FOR MAINTENANCE OF HEALTHY BALANCE OF MICROFLORA | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| CN-118620052-A | Novel mu-conotoxin peptide k-mu-CnIIIC and application thereof | 深圳肽盛生物科技有限公司 | 2024-09-10 | — | — | CN | disclosed |
| CN-118598963-A | Novel mu-conotoxin peptide dRK-mu-CnIIIC and application thereof | 深圳肽盛生物科技有限公司 | 2024-09-06 | — | — | CN | disclosed |
| CN-118574643-A | Conjugates that bind phosphatidylserine and Toll-like receptors | 三井有限公司 | 2024-08-30 | — | — | CN | disclosed |
| CN-118496336-A | Novel mu-conotoxin peptide dRR-mu-CnIIIC and application thereof | 深圳肽盛生物科技有限公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-118496335-A | Novel mu-conotoxin peptide dKR-mu-CnIIIC and application thereof | 深圳肽盛生物科技有限公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-118510537-A | Therapeutic peptidomimetics | 罗马大学 | 2024-08-16 | — | — | CN | disclosed |
| US-20240269292-A1 | INTRAVITREAL MITOCHONDRIAL-TARGETED PEPTIDE PRODRUGS AND METHODS OF USE | EYEDEA BIO, LLC | 2024-08-15 | — | — | US | disclosed |
| CN-117379444-B | Pharmaceutical composition containing zoledronic acid and capable of inhibiting side reaction and application thereof | 重庆医科大学 | 2024-08-13 | — | — | CN | disclosed |
| CN-118440156-A | Bionic cyclic peptide and application thereof | 郑州大学第一附属医院 | 2024-08-06 | — | — | CN | disclosed |
| EP-4164405-B1 | INCREASING THE METABOLIC ENERGY IN ANIMAL FEED | ALZCHEM TROSTBERG GMBH (DE) | 2024-07-31 | — | — | EP | disclosed |
| WO-2024155553-A1 | LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-25 | — | — | WO | disclosed |
| WO-2024155547-A2 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-25 | — | — | WO | disclosed |
| CN-118344453-A | Novel mu-conotoxin peptide r-mu-CnIIIC and application thereof | 深圳肽盛生物科技有限公司 | 2024-07-16 | — | — | CN | disclosed |
| EP-4395740-A1 | COMPOSITIONS AND METHODS FOR PROMOTING AND/OR MAINTAINING VAGINOVULVAL AND PERIANAL TISSUE VITALITY AND TISSUE HEALTH | Spinart, LLC (US) | 2024-07-10 | — | — | EP | disclosed |
| US-12029748-B2 | Synergistic composition for maintenance of healthy balance of microflora | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| EP-4387676-A2 | DELIVERY OF ANITSENSE OLIGOMERS BY MIRROR IMAGE PEPTIDES | Sarepta Therapeutics, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-118146336-A | Novel mu-conotoxin peptide dR-mu-CnIIIC and application thereof | 深圳肽盛生物科技有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118146338-A | Novel mu-conotoxin peptide dK-mu-CnIIIC and application thereof | 深圳肽盛生物科技有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118146337-A | Novel mu-conotoxin peptide dH-mu-CnIIIC and application thereof | 深圳肽盛生物科技有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-20240173423-A1 | CYCLIC PEPTIDYL INHIBITORS OF CAL-PDZ BINDING DOMAIN | OHIO STATE INNOVATION FOUNDATION | 2024-05-30 | — | — | US | disclosed |
| US-11987821-B2 | Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy | ENTRADA THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-11987647-B2 | Cyclic cell-penetrating peptides with one or more hydrophobic residues | OHIO STATE INNOVATION FOUNDATION (US) | 2024-05-21 | — | — | US | disclosed |
| WO-2024102993-A1 | CATIONICALLY-ENFRAMED HIGH DENSITY AROMATIC PEPTIDES | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2024-05-16 | — | — | WO | disclosed |
| US-20240158445-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-16 | — | — | US | disclosed |
| US-11975051-B1 | Therapeutic peptides and uses thereof | ELLISON SIOBHAN (US) | 2024-05-07 | — | — | US | disclosed |
| CN-117205305-B | Formulations and compositions of cabazitaxel | 珠海贝海生物技术有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117567639-A | Polypeptide conjugates for intracellular delivery of binding peptides | 俄亥俄州国家创新基金会 | 2024-02-20 | — | — | CN | disclosed |
| WO-2024026141-A2 | CYCLIC CELL-PENETRATING PEPTIDES AND USES THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20240033318-A1 | PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION | OHIO STATE INNOVATION FOUNDATION | 2024-02-01 | — | — | US | disclosed |
| CN-117466976-A | Parafrican loach gonadotrophin releasing hormone analogue and compound oxytocic and application thereof | 中国科学院水生生物研究所 | 2024-01-30 | — | — | CN | disclosed |
| CN-117417382-A | Iron-based complex nanoparticle with thermochromic, antibacterial activity and ammonia response, and preparation method and application thereof | 桂林理工大学 | 2024-01-19 | — | — | CN | disclosed |
| CN-117379444-A | Pharmaceutical composition containing zoledronic acid and capable of inhibiting side reaction and application thereof | 重庆医科大学 | 2024-01-12 | — | — | CN | disclosed |
| EP-4294820-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES | Ohio State Innovation Foundation (US) | 2023-12-27 | — | — | EP | disclosed |
| CN-117264283-A | High-performance multifunctional cellulose composite membrane and preparation method and application thereof | 桂林理工大学 | 2023-12-22 | — | — | CN | disclosed |
| WO-2023245016-A1 | INTERLEUKIN-13 BINDING CYCLIC OLIGOPEPTIDES AND METHODS OF USE THEREOF | B.A.I. LABORATORIES, LLC (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023242296-A1 | USE OF A MICROALGAE EXTRACT, ALONE OR IN COMBINATION, FOR IMPROVING COGNITIVE ABILITIES | MICROPHYT (FR) | 2023-12-21 | — | — | WO | disclosed |
| US-20230399362-A1 | INTERLEUKIN-13 BINDING CYCLIC OLIGOPEPTIDES AND METHODS OF USE THEREOF | B.A.I. LABORATORIES, LLC | 2023-12-14 | — | — | US | disclosed |
| CN-117205305-A | Formulations and compositions of cabazitaxel | 珠海贝海生物技术有限公司 | 2023-12-12 | — | — | CN | disclosed |
| US-11839642-B2 | Anti-angiogenin peptides, compositions, and methods of use | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230382953-A1 | TRANSCRIPTION ACTIVE COMPLEX TARGETING CANCER DRUG FROM VIRAL PROTEIN SEQUENCE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-30 | — | — | US | disclosed |
| US-20230382949-A1 | LINEAR APELIN RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-11-30 | — | — | US | disclosed |
| US-20230382950-A1 | CYCLIC APELIN RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-11-30 | — | — | US | disclosed |
| WO-2023215235-A2 | PEPTIDE INHIBITORS FOR CHROMODOMAIN HELICASE DNA BINDING PROTEIN 4 (CHD4) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-09 | — | — | WO | disclosed |
| CN-111447941-B | Polypeptide conjugates for intracellular delivery of binding peptides | 俄亥俄州国家创新基金会 | 2023-10-31 | — | — | CN | disclosed |
| US-11793884-B2 | Cyclic peptidyl inhibitors of CAL-PDZ binding domain | OHIO STATE INNOVATION FOUNDATION (US) | 2023-10-24 | — | — | US | disclosed |
| CN-116917337-A | Transcriptionally active complexes from viral protein sequences for targeting cancer drugs | 加利福尼亚大学董事会 | 2023-10-20 | — | — | CN | disclosed |
| US-20230322859-A1 | BICYCLIC PEPTIDYL INHIBITORS | OHIO STATE INNOVATION FOUNDATION | 2023-10-12 | — | — | US | disclosed |
| US-20230310540-A1 | PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | 2023-10-05 | — | — | US | disclosed |
| EP-3890765-B1 | D-ARG-2'6'-DMT-LYS-PHE-NH2 FOR USE IN TREATING OR PREVENTING SENGERS SYNDROME | STEALTH BIOTHERAPEUTICS INC (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20230284655-A1 | INCREASING THE METABOLIC ENERGY IN ANIMAL FEED | ALZCHEM TROSTBERG GMBH (DE) | 2023-09-14 | — | — | US | disclosed |
| CN-112055588-B | Formulations and compositions of cabazitaxel | 珠海贝海生物技术有限公司 | 2023-09-08 | — | — | CN | disclosed |
| US-20230270869-A1 | PHOSPHATIDYLSERINE-BINDING CONJUGATES | CANBAS CO., LTD. (JP) | 2023-08-31 | — | — | US | disclosed |
| EP-4232061-A1 | TRANSCRIPTION ACTIVE COMPLEX TARGETING CANCER DRUG FROM VIRAL PROTEIN SEQUENCE | The Regents of The University of California (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-115057922-B | SNACIP inducer of small molecule-nano antibody conjugate proximity effect and preparation method and application thereof | 哈尔滨工业大学 | 2023-08-01 | — | — | CN | disclosed |
| US-20230220010-A1 | BROAD-SPECTRUM ANTIVIRAL PEPTIDES | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | 2023-07-13 | — | — | US | disclosed |
| CN-115028704-B | Enzymolysis-resistant antibacterial peptide N1 and preparation method and application thereof | 东北农业大学 | 2023-07-07 | — | — | CN | disclosed |
| WO-2023126751-A1 | THERAPEUTICAL PEPTIDOMIMETIC | UNIVERSITA' DEGLI STUDI DI ROMA "LA SAPIENZA" (IT) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023126885-A1 | CONJUGATES BINDING PHOSPHATIDYLSERINE AND TOLL-LIKE RECEPTORS | CANBAS CO., LTD. (JP) | 2023-07-06 | — | — | WO | disclosed |
| US-11673919-B2 | Bicyclic peptidyl inhibitors | OHIO STATE INNOVATION FOUNDATION (US) | 2023-06-13 | — | — | US | disclosed |
| CN-116133528-A | Increasing metabolic energy in animal feed | 澳泽化学特罗斯特贝格有限公司 | 2023-05-16 | — | — | CN | disclosed |
| US-11634507-B2 | Dendritic gold nanoparticles and methods of synthesis | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2023-04-25 | — | — | US | disclosed |
| EP-4164405-A1 | INCREASING THE METABOLIC ENERGY IN ANIMAL FEED | AlzChem Trostberg GmbH (DE) | 2023-04-19 | — | — | EP | disclosed |
| US-20230106131-A1 | POLYPEPTIDE CONJUGATES FOR INTRACELLULAR DELIVERY OF STAPLED PEPTIDES | OHIO STATE INNOVATION FOUNDATION | 2023-04-06 | — | — | US | disclosed |
| WO-2023034515-A2 | DELIVERY OF ANITSENSE OLIGOMERS BY MIRROR IMAGE PEPTIDES | SAREPTA THERAPEUTICS, INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| WO-2023034446-A1 | COMPOSITIONS AND METHODS FOR PROMOTING AND/OR MAINTAINING VAGINOVULVAL AND PERIANAL TISSUE VITALITY AND TISSUE HEALTH | Spinart, LLC (US) | 2023-03-09 | — | — | WO | disclosed |
| US-11576946-B2 | Peptidyl inhibitors of calcineurin-NFAT interaction | OHIO STATE INNOVATION FOUNDATION (US) | 2023-02-14 | — | — | US | disclosed |
| EP-4129318-A1 | PROTEIN-BASED PHARMACEUTICAL COMPOSITION WITH NEUROPROTECTIVE, IMMUNOMODULATING, ANTI-INFLAMMATORY AND ANTIMICROBIAL ACTIVITY | Centro Nacional de Biopreparados (CU) | 2023-02-08 | — | — | EP | disclosed |
| US-20230020092-A1 | COMPOSITIONS FOR DELIVERY OF ANTISENSE COMPOUNDS | ENTRADA THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| EP-3197912-B1 | LIPIDATED AMIDE-BASED INSULIN PRODRUGS | UNIV INDIANA RES & TECH CORP (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-4110467-A1 | BROAD-SPECTRUM ANTIVIRAL PEPTIDES | The Administrators of the Tulane Educational Fund (US) | 2023-01-04 | — | — | EP | disclosed |
| US-20220401585-A1 | A UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-TARGETING PEPTIDE | RIGSHOSPITALET (DK) | 2022-12-22 | — | — | US | disclosed |
| WO-2022256412-A2 | EXTENDED RELEASE DRUG DELIVERY SYSTEM FOR OCULAR DRUGS AND METHODS OF USE | EYEDEA BIO, LLC (US) | 2022-12-08 | — | — | WO | disclosed |
| US-11510991-B2 | Polypeptide conjugates for intracellular delivery of stapled peptides | OHIO STATE INNOVATION FOUNDATION (US) | 2022-11-29 | — | — | US | disclosed |
| EP-4087595-A1 | PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF | The Administrators of the Tulane Educational Fund (US) | 2022-11-16 | — | — | EP | disclosed |
| US-20220347262-A1 | Compositions and Formulations and Methods of Production and Use Thereof | AXCELLA (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC | 2022-11-03 | — | — | US | disclosed |
| CN-115209908-A | Protein-based pharmaceutical compositions with neuroprotective, immunomodulatory, anti-inflammatory and antimicrobial activities | 国家生物医学中心 | 2022-10-18 | — | — | CN | disclosed |
| US-20220315631-A1 | STAPLED BETA-CATENIN LIGANDS | OHIO STATE INNOVATION FOUNDATION | 2022-10-06 | — | — | US | disclosed |
| US-20220296683-A1 | ORAL DELIVERY SYSTEM | UNIVERSITY COLLEGE DUBLIN (IE) | 2022-09-22 | — | — | US | disclosed |
| EP-4058032-A1 | COMPOSITIONS FOR DELIVERY OF ANTISENSE COMPOUNDS | Entrada Therapeutics, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| EP-2771696-B1 | METHODS MAKING USE OF PANELS OF METABOLITES FOR THE DIAGNOSIS AND DIFFERENTIATION OF NEONATAL ENCEPHALOPATHY | INFANDX AG (DE) | 2022-09-14 | — | — | EP | disclosed |
| US-20220281920-A1 | BICYCLIC PEPTIDYL INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-09-08 | — | — | US | disclosed |
| WO-2022178379-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES | OHIO STATE INNOVATION FOUNDATION (US) | 2022-08-25 | — | — | WO | disclosed |
| US-11413265-B2 | Formulations and compositions of Cabazitaxel | ZHUHAI BEIHAI BIOTECH CO., LTD. (CN) | 2022-08-16 | — | — | US | disclosed |
| EP-4021408-A1 | ORAL DELIVERY SYSTEM | University College Dublin (IE) | 2022-07-06 | — | — | EP | disclosed |
| EP-4021473-A1 | STAPLED BETA-CATENIN LIGANDS | Ohio State Innovation Foundation (US) | 2022-07-06 | — | — | EP | disclosed |
| US-11357824-B2 | Nutritive polypeptides and formulations thereof, and methods of production and use thereof | AXCELLA HEALTH INC. (US) | 2022-06-14 | — | — | US | disclosed |
| CN-114555623-A | Urokinase plasminogen activator receptor targeting peptides | 丹麦国家医院 | 2022-05-27 | — | — | CN | disclosed |
| EP-3999094-A1 | A UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-TARGETING PEPTIDE | Rigshospitalet (DK) | 2022-05-25 | — | — | EP | disclosed |
| US-11339192-B2 | Bicyclic peptidyl inhibitors | OHIO STATE INNOVATION FOUNDATION (US) | 2022-05-24 | — | — | US | disclosed |
| WO-2022087221-A1 | TRANSCRIPTION ACTIVE COMPLEX TARGETING CANCER DRUG FROM VIRAL PROTEIN SEQUENCE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-28 | — | — | WO | disclosed |
| US-11313866-B2 | Method of diagnosing and treating asphyxia | INFANDX AG (DE) | 2022-04-26 | — | — | US | disclosed |
| WO-2022058330-A1 | AN ANTIMICROBIAL PEPTIDE (AMP) OR ANALOGUE THEREOF COMPRISING AT LEAST ONE PEPTIDOMIMETIC EXTENSION FOR USE AS AN ANTIMICROBIAL COMPOUND AGAINST AN INFECTIOUS DISEASE | Københavns Universitet (DK) | 2022-03-24 | — | — | WO | disclosed |
| EP-3965724-A1 | FORMULATIONS AND METHODS FOR PREPARING STABLE COSMETIC COMPOSITIONS | Spinart, LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| US-11266743-B2 | Peptide compositions and methods of use thereof | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2022-03-08 | — | — | US | disclosed |
| CN-114126653-A | GHRH antagonists for use in methods of treating sarcoidosis | 迈阿密大学 | 2022-03-01 | — | — | CN | disclosed |
| CN-114057829-A | Solid-phase synthesis method of N-methylated polypeptide | 江苏金斯瑞生物科技有限公司 | 2022-02-18 | — | — | CN | disclosed |
| US-20210052540-A1 | FORMULATIONS AND COMPOSITIONS OF CABAZITAXEL | ZHUHAI BEIHAI BIOTECH CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
| CN-112055588-A | Formulations and compositions of cabazitaxel | 珠海贝海生物技术有限公司 | 2020-12-08 | — | — | CN | disclosed |
| US-10514383-B2 | Diagnosis and treatment of neonatal encephalopathy | INFANDX AG (DE) | 2019-12-24 | — | — | US | disclosed |
| WO-2019204738-A1 | FORMULATIONS AND COMPOSITIONS OF CABAZITAXEL | ZHUHAI BEIHAI BIOTECH CO., LTD. (CN) | 2019-10-24 | — | — | WO | disclosed |
| US-9976163-B2 | Method for preventing reduction of polypeptide by adding amino acid to culture solution | KYOWA HAKKO KIRIN CO., LTD (JP) | 2018-05-22 | — | — | US | disclosed |
| US-20180011111-A1 | Method of Diagnosing and Treating Asphyxia | INFANDX AG (DE) | 2018-01-11 | — | — | US | disclosed |
| US-9791459-B2 | Method of diagnosing and treating asphyxia | INFANDX AG (DE) | 2017-10-17 | — | — | US | disclosed |
| CN-106999973-A | System and method for discharging edible material | 阿甘芳香和精细化工有限公司 | 2017-08-01 | — | — | CN | disclosed |
| US-20150275259-A1 | METHOD FOR PREVENTING REDUCTION OF POLYPEPTIDE BY ADDING AMINO ACID TO CULTURE SOLUTION | KYOWA HAKKO KIRIN CO., LTD (JP) | 2015-10-01 | — | — | US | disclosed |
| EP-2905342-A1 | METHOD FOR PREVENTING POLYPEPTIDE REDUCTION BY ADDING AMINO ACID TO LIQUID CULTURE MEDIUM | Kyowa Hakko Kirin Co., Ltd. (JP) | 2015-08-12 | — | — | EP | disclosed |
| US-20140308687-A1 | Method and Use of Metabolites for the Diagnosis and Differentiation of Neonatal Encephalopathy | INFANDX AG (DE) | 2014-10-16 | — | — | US | disclosed |
| EP-2623090-A1 | Special biofilm-reducing toothpaste | Henkel AG&Co. KGAA (DE) | 2013-08-07 | — | — | EP | disclosed |
| US-20120208282-A1 | Method For Normalization in Metabolomics Analysis Methods with Endogenous Reference Metabolites. | BIOCRATES LIFE SCIENCES AG | 2012-08-16 | — | — | US | disclosed |
| US-20120136581-A1 | Method of Diagnosing Asphyxia | BIOCRATES LIFE SCIENCES AG (AT) | 2012-05-31 | — | — | US | disclosed |
| EP-2427773-A1 | METHOD OF DIAGNOSING ASPHYXIA | Keller, Matthias (DE) | 2012-03-14 | — | — | EP | disclosed |
| EP-2270699-A1 | Method for normalization in metabolomics analysis methods with endogenous reference metabolites | BIOCRATES Life Sciences AG (AT) | 2011-01-05 | — | — | EP | disclosed |
| WO-2010128054-A1 | METHOD OF DIAGNOSING ASPHYXIA | BIOCRATES LIFE SCIENCES AG (AT) | 2010-11-11 | — | — | WO | disclosed |
| US-20080206169-A1 | Personal care composition | PROCTER & GAMBLE COMPANY, THE | 2008-08-28 | — | — | US | disclosed |
| WO-2008063441-A2 | PERSONAL CARE COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008063441-A2 | PERSONAL CARE COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (48 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250090675-A1 | POLYPEPTIDE CONJUGATES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | LNPEP, PCNP, NASP | NOS2 2895/4885CYP2C19 4870/4885CYP1A2 4882/4885 |
| US-20240269292-A1 | INTRAVITREAL MITOCHONDRIAL-TARGETED PEPTIDE PRODRUGS AND METHODS OF USE | PDF, PITRM1, ATP5PD | NOS2 2731/4885CYP2C19 980/4885CYP1A2 3515/4885 |
| US-20260115301-A1 | INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | SLC7A1, SRM, SLC6A19 | NOS2 887/4885CYP2C19 4740/4885CYP1A2 4860/4885 |
| US-11987821-B2 | Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy | PYGB, FPGS, GLS2 | NOS2 1559/4885CYP2C19 2924/4885CYP1A2 4126/4885 |
| US-20250011777-A1 | DELIVERY OF ANITSENSE OLIGOMERS BY MIRROR IMAGE PEPTIDES | MYOF, IAPP, MTPN | NOS2 1503/4885CYP2C19 4881/4885CYP1A2 4868/4885 |
| US-20240368227-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH ONE OR MORE HYDROPHOBIC RESIDUES | VIP, LNPEP, TAP1 | NOS2 3501/4885CYP2C19 4825/4885CYP1A2 4883/4885 |
| US-12171838-B2 | Polypeptide conjugates for intracellular delivery of nucleic acids | LNPEP, PCNP, NASP | NOS2 2895/4885CYP2C19 4870/4885CYP1A2 4882/4885 |
| US-20220281920-A1 | BICYCLIC PEPTIDYL INHIBITORS | NFKBIA, IKBKG, NFRKB | NOS2 2490/4885CYP2C19 4709/4885CYP1A2 4850/4885 |
| US-20250115885-A1 | COMPOSITIONS AND METHODS FOR TREATING MITOCHONDRIAL NEUROGASTROINTESTINAL ENCEPHALOPATHY | PYGB, FPGS, GLS2 | NOS2 1559/4885CYP2C19 2924/4885CYP1A2 4126/4885 |
| US-11793884-B2 | Cyclic peptidyl inhibitors of CAL-PDZ binding domain | CNBP, CALU, CLSPN | NOS2 4417/4885CYP2C19 4564/4885CYP1A2 4820/4885 |
| US-12441777-B2 | GLP-1 receptor antagonists | GLP1R, GIPR, GPR119 | NOS2 3663/4885CYP2C19 3702/4885CYP1A2 2846/4885 |
| US-20230382950-A1 | CYCLIC APELIN RECEPTOR AGONISTS | APLNR, MTNR1A, EDNRA | NOS2 2669/4885CYP2C19 4529/4885CYP1A2 2838/4885 |
| US-12528840-B2 | Transcription active complex targeting cancer drug from viral protein sequence | MYC, MYCBP, TPT1 | NOS2 3349/4885CYP2C19 4352/4885CYP1A2 4678/4885 |
| US-20230020092-A1 | COMPOSITIONS FOR DELIVERY OF ANTISENSE COMPOUNDS | HNRNPAB, SNRPE, HNRNPA2B1 | NOS2 3550/4885CYP2C19 4881/4885CYP1A2 4884/4885 |
| US-11673919-B2 | Bicyclic peptidyl inhibitors | NFKBIA, IKBKG, NFRKB | NOS2 2490/4885CYP2C19 4709/4885CYP1A2 4850/4885 |
| US-12508295-B2 | Piscine-derived PYY peptides for use in treating a metabolic disorder | DPP4, DPP9, VIP | NOS2 3413/4885CYP2C19 1017/4885CYP1A2 3662/4885 |
| US-20260008812-A1 | CELL-PENETRATING PEPTIDE COMPOUNDS | SLC38A7, SLC7A1, SLC6A7 | NOS2 903/4885CYP2C19 3568/4885CYP1A2 4033/4885 |
| US-20260125426-A1 | CYCLIC CELL-PENETRATING PEPTIDES AND USES THEREOF | SLC7A1, TAP1, SLC7A5 | NOS2 42/4885CYP2C19 3698/4885CYP1A2 4299/4885 |
| US-20260070947-A1 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | SLC7A1, SLC38A7, SLC6A19 | NOS2 1698/4885CYP2C19 4313/4885CYP1A2 4771/4885 |
| US-20230322859-A1 | BICYCLIC PEPTIDYL INHIBITORS | NFKBIA, IKBKG, NFRKB | NOS2 2490/4885CYP2C19 4709/4885CYP1A2 4850/4885 |
| US-12281181-B2 | Bicyclic peptidyl inhibitors | NFKBIA, IKBKG, NFRKB | NOS2 2490/4885CYP2C19 4709/4885CYP1A2 4850/4885 |
| US-20260070948-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH CARGO | SLC7A1, SLC38A7, SLC6A19 | NOS2 1576/4885CYP2C19 4410/4885CYP1A2 4695/4885 |
| US-20220401585-A1 | A UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-TARGETING PEPTIDE | PLAUR, PLAU, PLG | NOS2 4342/4885CYP2C19 3971/4885CYP1A2 4550/4885 |
| US-20240173423-A1 | CYCLIC PEPTIDYL INHIBITORS OF CAL-PDZ BINDING DOMAIN | CNBP, CALU, CLSPN | NOS2 4417/4885CYP2C19 4564/4885CYP1A2 4820/4885 |
| US-11413265-B2 | Formulations and compositions of Cabazitaxel | ALB, NRAS, KRAS | NOS2 2883/4885CYP2C19 1934/4885CYP1A2 3484/4885 |
| US-20230399362-A1 | INTERLEUKIN-13 BINDING CYCLIC OLIGOPEPTIDES AND METHODS OF USE THEREOF | CXCL10, IL23R, CCL11 | NOS2 1158/4885CYP2C19 4836/4885CYP1A2 4844/4885 |
| US-20230106131-A1 | POLYPEPTIDE CONJUGATES FOR INTRACELLULAR DELIVERY OF STAPLED PEPTIDES | VIP, IAPP, TAP1 | NOS2 3765/4885CYP2C19 4865/4885CYP1A2 4885/4885 |
| US-20260001916-A1 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | SLC7A1, SLC38A7, SLC6A19 | NOS2 1527/4885CYP2C19 3666/4885CYP1A2 4450/4885 |
| US-12115224-B2 | Polypeptide conjugates for intracellular delivery of stapled peptides | VIP, IAPP, TAP1 | NOS2 3765/4885CYP2C19 4865/4885CYP1A2 4885/4885 |
| US-20260008813-A1 | CELL-PENETRATING PEPTIDE COMPOUNDS | SLC7A1, SLC38A7, SLC6A19 | NOS2 1468/4885CYP2C19 3887/4885CYP1A2 4565/4885 |
| US-20210052540-A1 | FORMULATIONS AND COMPOSITIONS OF CABAZITAXEL | ALB, NRAS, KRAS | NOS2 2883/4885CYP2C19 1934/4885CYP1A2 3484/4885 |
| US-11510991-B2 | Polypeptide conjugates for intracellular delivery of stapled peptides | VIP, IAPP, TAP1 | NOS2 3765/4885CYP2C19 4865/4885CYP1A2 4885/4885 |
| US-12329799-B2 | Peptidyl inhibitors of calcineurin-NFAT interaction | CHP1, NFATC1, PPP3R1 | NOS2 1959/4885CYP2C19 4657/4885CYP1A2 4838/4885 |
| US-20250270258-A1 | BICYCLIC PEPTIDYL INHIBITORS | NFKBIA, IKBKG, NFRKB | NOS2 2490/4885CYP2C19 4709/4885CYP1A2 4850/4885 |
| US-20240158445-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES | SLC3A2, SLC7A1, ARGLU1 | NOS2 2802/4885CYP2C19 4848/4885CYP1A2 4884/4885 |
| US-20260073030-A1 | METHODS, SYSTEMS, APPARATUSES, AND DEVICES FOR FACILITATING SELF-OPTIMIZABLE BIOMETRIC IDENTITY VERIFICATION OF USERS | BMP2, BMP1, BMP6 | NOS2 3190/4885CYP2C19 1644/4885CYP1A2 1949/4885 |
| US-20220315631-A1 | STAPLED BETA-CATENIN LIGANDS | CTNNB1, CTNNBL1, CTNND1 | NOS2 4855/4885CYP2C19 4863/4885CYP1A2 4884/4885 |
| US-11339192-B2 | Bicyclic peptidyl inhibitors | NFKBIA, IKBKG, NFRKB | NOS2 2490/4885CYP2C19 4709/4885CYP1A2 4850/4885 |
| US-20220296683-A1 | ORAL DELIVERY SYSTEM | GLP1R, GIPR, IAPP | NOS2 1461/4885CYP2C19 3321/4885CYP1A2 4535/4885 |
| US-20240360174-A1 | CELL-PENETRATING PEPTIDE SEQUENCES | VIP, LNPEP, NGLY1 | NOS2 3580/4885CYP2C19 4031/4885CYP1A2 4838/4885 |
| US-12496350-B2 | Cyclic peptidyl inhibitors of CAL-PDZ binding domain | CNBP, CALU, CLSPN | NOS2 4417/4885CYP2C19 4564/4885CYP1A2 4820/4885 |
| US-20250145666-A1 | INTERLEUKIN-13 BINDING CYCLIC OLIGOPEPTIDES AND METHODS OF USE THEREOF | CXCL10, IL23R, CCL11 | NOS2 1158/4885CYP2C19 4836/4885CYP1A2 4844/4885 |
| US-20240033318-A1 | PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION | CHP1, NFATC1, PPP3R1 | NOS2 1959/4885CYP2C19 4657/4885CYP1A2 4838/4885 |
| US-20230382949-A1 | LINEAR APELIN RECEPTOR AGONISTS | APLNR, MTNR1A, EDNRA | NOS2 2806/4885CYP2C19 4136/4885CYP1A2 2600/4885 |
| US-11987647-B2 | Cyclic cell-penetrating peptides with one or more hydrophobic residues | VIP, LNPEP, TAP1 | NOS2 3501/4885CYP2C19 4825/4885CYP1A2 4883/4885 |
| US-11576946-B2 | Peptidyl inhibitors of calcineurin-NFAT interaction | CHP1, NFATC1, PPP3R1 | NOS2 1959/4885CYP2C19 4657/4885CYP1A2 4838/4885 |
| US-20260069656-A1 | Nutritive Polypeptides and Formulations Thereof, and Methods of Production and Use Thereof | TTPA, VIP, GC | NOS2 363/4885CYP2C19 1197/4885CYP1A2 1972/4885 |
| US-12180307-B2 | Interleukin-13 binding cyclic oligopeptides and methods of use thereof | CXCL10, IL23R, CCL11 | NOS2 1158/4885CYP2C19 4836/4885CYP1A2 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.